Philip Vincent, MD
Child & Adolescent Psychiatry · New York, NYNPI 1114243524
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 127 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Johnson & Johnson at 28.7% of the total.
Across 127 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$557
- Sunovion Pharmaceuticals Inc.$444
- Otsuka America Pharmaceutical, Inc.$394
- Teva Pharmaceuticals USA, Inc.$181
- AbbVie$156
- Alkermes, Inc.$139
- plus $73 from 3 others
What the payments were for
- Food & beverage$1,943100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 38 | $557 |
| Sunovion Pharmaceuticals Inc. | 29 | $444 |
| Otsuka America Pharmaceutical, Inc. | 26 | $394 |
| Teva Pharmaceuticals USA, Inc. | 10 | $181 |
| AbbVie | 11 | $156 |
| Alkermes, Inc. | 9 | $139 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Bioxcel Therapeutics, Inc. | 1 | $23 |
| Indivior Inc. | 1 | $15 |
How this compares
$1,943 in reported general payments places this provider in the 85th percentile of 317 child & adolescent psychiatry providers in New York.
See all child & adolescent psychiatry providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mirtazapine | 12 | $209 |
| Quetiapine Fumarate | 12 | $176 |
| Hydroxyzine Hcl | 14 | $129 |
| Pantoprazole Sodium | 13 | $104 |
| Gabapentin | 18 | $100 |
| Sertraline Hcl | 12 | $86 |
| Fluoxetine Hcl | 12 | $78 |
| Rosuvastatin Calcium | 13 | $76 |
| Trazodone Hcl | 23 | $62 |
| Levothyroxine Sodium | 11 | $43 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in New York
- Matthew LorberNew York$398K
- Jeffrey NewcornNew York$165K
- Iliyan IvanovNew York$38K
- Melvin OatisNew York$35K
- Alexander KolevzonNew York$10K
- Moira RynnNew York$8K
- Jeremy Veenstra-VanderweeleNew York$7K
- Eric AlceraNew York$6K
- Adam CohenNew York$3K
- Shannon DelaneyNew York$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.